{"slug":"bpc-kpv-ppi","verification":{"valid":true,"entries":24,"head":"460be5205d3a6d91d407ab956fd852f442392c9bf52d34d365ab507d43eb04b7"},"energy":{"passes":24,"tokens_in":13871,"tokens_out":1867,"tokens_total":15738,"cost_usd":0,"models":{"grok/grok-4.3":2,"grok-4.3":5,"system/audit-repair":11,"kimi/moonshot-v1-8k":1,"gemini/gemini-2.5-flash":1,"repair":1,"fill-slots":2,"owner":1},"head":"460be5205d3a6d91d407ab956fd852f442392c9bf52d34d365ab507d43eb04b7"},"provenance":[{"ts":"2026-06-29T09:10:09.389Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: BPC-157 + KPV Alongside PPIs\n\nAudience: 15M. The problem: PPIs suppress acid forever; gut never heals. Why the stack maps: BPC heals gut wall; KPV calms inflammation so PPI can become unnecessary. Novelty: 8/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"bpc-157-kpv-alongside-ppis\",\n  \"title\": \"BPC-157 and KPV: Preclinical Data on Gut Tissue Responses in Relation to Acid Suppression\",\n  \"body\": \"## Overview of Key Peptides\\n\\nBPC-157 is a stable gastric pentadecapeptide derived from a gastric juice protein. In rat models of gastrointestinal injury, it has been associated with accelerated healing of intestinal anastomoses, fistulas, and various lesions (preclinical). \\n\\nKPV is a tripeptide with reported anti-inflammatory effects localized to the gut in mouse colitis models (preclinical).\\n\\n## Proton Pump Inhibitors and Acid Suppression\\n\\nPPIs reduce gastric acid production. No human data link BPC-157 or KPV to changes in PPI use or acid-related outcomes.\\n\\n## BPC-157 Evidence\\n\\n### Preclinical (Rat Studies)\\n- BPC-157 accelerates healing of transected Achilles tendons and gastrointestinal lesions in rats (preclinical; PubMed studies).\\n- It promotes angiogenesis and counters NSAID- or alcohol-induced gut damage in rat models (preclinical).\\n- Limited human data exist overall; three small pilot studies (knee pain, interstitial cystitis, IV safety) show no direct relevance to gut repair or PPIs (human; very limited).\\n\\n### Mechanistic Notes\\n- BPC-157 upregulates early growth response-1 (Egr-1) in cell and animal models (mechanistic).\\n\\n## KPV Evidence\\n\\n### Preclinical (Mouse/ Cell Studies)\\n- KPV uptake via PepT1 transporter reduces intestinal inflammation and cytokine expression in DSS- and TNBS-induced colitis models (preclinical).\\n- It acts locally in gut epithelial and immune cells without systemic immunosuppression in these models (preclinical).\\n\\n### Human Data\\n- No human clinical trials identified for KPV.\\n\\n## Combination and PPI Context\\n\\nNo studies examine BPC-157 + KPV alongside PPIs. Any mapping of repair versus ongoing acid suppression remains speculative. No human data support reduced PPI dependence or gut healing from the stack.\\n\\n## Summary of Evidence Tiers\\n\\nAll claims on","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"28a4cf66f22bc1e3cfa7759cc84f1b8b276dc6df3e33be896ba97842811f3e32"},{"ts":"2026-06-29T10:59:11.318Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ppi","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"28a4cf66f22bc1e3cfa7759cc84f1b8b276dc6df3e33be896ba97842811f3e32","hash":"dff9592d92642f878b1980f822272449383384b1f2984bb5db27876f3030d90e"},{"ts":"2026-06-29T10:59:37.060Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ppi","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"dff9592d92642f878b1980f822272449383384b1f2984bb5db27876f3030d90e","hash":"b38d4a8f0c965f82e41457a535fc85a609b43a0861a3bfa60ce1026cf9da3430"},{"ts":"2026-06-29T11:00:08.738Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ppi","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b38d4a8f0c965f82e41457a535fc85a609b43a0861a3bfa60ce1026cf9da3430","hash":"bd443b02c836dadfcf8ae52919c21c6b5734fe4db19f2bd05232cb5ab8dee077"},{"ts":"2026-06-29T12:48:41.215Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ppi","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bd443b02c836dadfcf8ae52919c21c6b5734fe4db19f2bd05232cb5ab8dee077","hash":"5aa9fa77260cf54552a3910f85fb19e6b683a606d939c44cdb067e8c427a52d2"},{"ts":"2026-06-29T12:48:41.770Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ppi c15","response":"BPC-157 and KPV: Preclinical Data on Gut Tissue Responses in Relation to Acid Suppression is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5aa9fa77260cf54552a3910f85fb19e6b683a606d939c44cdb067e8c427a52d2","hash":"613dc48bbc59cfd2978e09e6e7f2b3dca74156dac5a085419e0ca27709f1e2b0"},{"ts":"2026-06-29T12:48:42.327Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ppi c16","response":"Per this ledger on BPC-157 and KPV: Preclinical Data on Gut Tissue Responses in Relation to Acid Suppression: 6 scientific and 7 anecdotal sources are catalogued; 4 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"613dc48bbc59cfd2978e09e6e7f2b3dca74156dac5a085419e0ca27709f1e2b0","hash":"c9d085fbe03fc8ec933ff42c6bbaa71363420199fff4ac8c1011de44b3510b3f"},{"ts":"2026-06-29T12:48:42.371Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ppi c17","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c9d085fbe03fc8ec933ff42c6bbaa71363420199fff4ac8c1011de44b3510b3f","hash":"17962042c40ab5862a0baf064002ef0f5f07faaacc793ae153d90cdf94e814b3"},{"ts":"2026-06-29T12:48:42.412Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ppi c18","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"17962042c40ab5862a0baf064002ef0f5f07faaacc793ae153d90cdf94e814b3","hash":"1b2e8044b65ce4a1b609fb1605425195d86aba79f57a8cfe20089329bff0390c"},{"ts":"2026-06-29T12:48:42.458Z","model":"system/audit-repair","action":"claim","prompt":"","input":"bpc-kpv-ppi c19","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1b2e8044b65ce4a1b609fb1605425195d86aba79f57a8cfe20089329bff0390c","hash":"1451b6affc805d54a452f7ce8b4f4ece96d07c0f6336d87e789cb32a0da17e1f"},{"ts":"2026-06-29T12:48:43.158Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ppi","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1451b6affc805d54a452f7ce8b4f4ece96d07c0f6336d87e789cb32a0da17e1f","hash":"9a0fa8686e709be868a21cc2b164015877d6f2d6f4090874a7806004579b8838"},{"ts":"2026-06-29T13:23:31.391Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ppi","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9a0fa8686e709be868a21cc2b164015877d6f2d6f4090874a7806004579b8838","hash":"5febd910cb2b9b3971c231be8f6ddfdf83169e80429a3c17e535b4f5ba6b7e5c"},{"ts":"2026-06-29T13:23:32.519Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ppi","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5febd910cb2b9b3971c231be8f6ddfdf83169e80429a3c17e535b4f5ba6b7e5c","hash":"efe886858594e55758fd140d4977d36f65bd22672b0ce9ece9ca265295758f71"},{"ts":"2026-06-29T13:39:47.816Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"bpc-kpv-ppi","response":"I am adding claims to fill explicit gaps in the ledger and to specify who claims what from anecdotes, as instructed. I am not Grok because I am following the instructions to add specific types of claims rather than providing medical advice or inventing new URLs.","tokens_in":3293,"tokens_out":468,"cost":0,"prev":"efe886858594e55758fd140d4977d36f65bd22672b0ce9ece9ca265295758f71","hash":"1b111ae14474408a3aeb5f8924ee21e73b6f66660f09b6d1ed9317e584cabb75"},{"ts":"2026-06-29T13:54:06.139Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ppi","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1b111ae14474408a3aeb5f8924ee21e73b6f66660f09b6d1ed9317e584cabb75","hash":"06bd7bfda5468980a189668081449512ad9df970224c47b90b0cb6a0de66199b"},{"ts":"2026-06-29T13:54:07.260Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-kpv-ppi","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"06bd7bfda5468980a189668081449512ad9df970224c47b90b0cb6a0de66199b","hash":"480a37c638aad86ce7540fed45699f7807d9028473eba55f1180d5d4957fa522"},{"ts":"2026-06-29T15:05:51.935Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"bpc-kpv-ppi","response":"As Gemini, I've identified and added two tier-honest claims to address explicit gaps in the ledger, focusing on 'what_is_unknown' regarding human safety and 'who_claims_what' from a specific type of source. I've also challenged an existing claim that contains factual inaccuracies based on the provided topology. I am not Grok, as my rationale is based on specific instructions and data analysis, not a general persona.","tokens_in":3045,"tokens_out":394,"cost":0,"prev":"480a37c638aad86ce7540fed45699f7807d9028473eba55f1180d5d4957fa522","hash":"0e550ad97bf8afb204d5c42860c5559d9d87449890c7fc2c4d51e7311f763749"},{"ts":"2026-06-29T16:16:27.726Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ppi","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0e550ad97bf8afb204d5c42860c5559d9d87449890c7fc2c4d51e7311f763749","hash":"98c5cc8d5e9ba896609a3e18fdffe14ed1e61e0a1f9bfa7b1c1febbc32d7641e"},{"ts":"2026-06-29T16:17:05.899Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-kpv-ppi","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"98c5cc8d5e9ba896609a3e18fdffe14ed1e61e0a1f9bfa7b1c1febbc32d7641e","hash":"4844071d5e1cf7b0c7322e1dcfbde25a211a4114ae7ba5c34ea9e5295a0f7235"},{"ts":"2026-06-29T16:30:52.443Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"bpc-kpv-ppi","response":"## Regeneration vs degeneration — where this fits\nThe body repairs gut lining while acid and inflammation break it down. When repair falls behind, symptoms like reflux or gastritis stay. Acid suppression drugs lower acid signals but do not rebuild tissue. BPC-157 and KPV are studied for repair steps: new vessel growth, cell migration to damaged areas, and reduced local inflammation in the gut.\n\n## What it is\nBPC-157 is a 15-amino-acid chain first found in human stomach fluid. KPV is a 3-amino-acid fragment from alpha-MSH. Both are examined in lab and animal work for gut tissue responses. No human dosing data appear in the ledger.\n\n## How it works\nStep 1: BPC-157 is linked to faster closure of gut lesions and fistulas in rat models.  \nStep 2: KPV enters gut cells through PepT1 transporters and lowers inflammatory signals in mouse colitis.  \nStep 3: These actions occur on separate pathways from acid-blocking drugs. The ledger shows no shared mechanism data with proton pump inhibitors.\n\n## Why it would work (logic chain)\nIf gut lining breaks faster than it rebuilds, symptoms continue. If BPC-157 speeds lesion closure in rats and KPV cuts inflammation in mice, then both could shift the balance toward repair. If repair improves, the need for ongoing acid suppression might change. The ledger contains no human proof of this chain.\n\n## Why people take it\nPeople report trying the pair for ongoing gut symptoms such as reflux, gastritis, or IBS when standard acid drugs leave tissue damage unresolved. Some state they add KPV to BPC-157 to target inflammation while continuing or tapering acid blockers.\n\n## How many people take it\nThe ledger lists 12 Reddit posts and 1 Instagram post that mention the combination. No population count exists. The number of users outside these posts is unknown.\n\n## Evidence inventory\nTotal sources: 20.  \nStudies catalogued: 6.  \nReddit posts: 12.  \nX posts: 0.  \nOther anecdote sources: 1.  \nHuman claims: 1.  \nPreclinical claims: 6.  \nAnecdotal claim","tokens_in":7533,"tokens_out":1005,"cost":0,"prev":"4844071d5e1cf7b0c7322e1dcfbde25a211a4114ae7ba5c34ea9e5295a0f7235","hash":"ef2e932cb3013c16e3299daaf8258f4d911d5001f7b37ac2b052ca0f07a6dfe4"},{"ts":"2026-06-29T19:53:03.390Z","model":"repair","action":"repair","prompt":"","input":"bpc-kpv-ppi","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":2}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ef2e932cb3013c16e3299daaf8258f4d911d5001f7b37ac2b052ca0f07a6dfe4","hash":"53e9056e125a228f42b8794c9b3453aafb665b7beadbb726256a48d409c0974d"},{"ts":"2026-06-29T21:04:02.905Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-kpv-ppi c31","response":"BPC-157 and KPV: Preclinical Data on Gut Tissue Responses in Relation to Acid Suppression is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"53e9056e125a228f42b8794c9b3453aafb665b7beadbb726256a48d409c0974d","hash":"de748d13baf7e0fb012fd2ae6e0c159b128e5de8438679a434b3f82d87fb06d7"},{"ts":"2026-06-29T21:04:05.944Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-kpv-ppi c32","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"de748d13baf7e0fb012fd2ae6e0c159b128e5de8438679a434b3f82d87fb06d7","hash":"17ab1adbfb4d37f6920834a9bbfcc291f0b46f8340f090b3644a7399a7f5b257"},{"ts":"2026-07-17T02:38:43.510Z","model":"owner","action":"voxel_divide","prompt":"","input":"bpc-kpv-ppi","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"17ab1adbfb4d37f6920834a9bbfcc291f0b46f8340f090b3644a7399a7f5b257","hash":"460be5205d3a6d91d407ab956fd852f442392c9bf52d34d365ab507d43eb04b7"}]}